News
20 February 2026
From Quality to Public Trust
In the healthcare industry, public trust is not built overnight. It grows through consistent quality assurance, adherence to standards, and contributions that are tangibly felt by society. As demands for transparency continue to rise, healthcare companies are expected not only to deliver good products, but also to establish accurate and…
3 February 2026
Dexa Medica Receives the 2026 BPOM Achievement Award as Indonesia’s Leading Phytopharmaceutical Company
Dexa Medica has once again affirmed its role as a pioneer in Indonesia’s pharmaceutical industry through an award presented by the National Agency of Drug and Food Control (BPOM) of the Republic of Indonesia. The BPOM Achievement Award 2026 in the category of Pioneer with the Highest Number of Phytopharmaceutical…
30 January 2026
Dexa Group’s Consistent Reputation Management Wins the 8th Indonesia Public Relations Awards
Winning the award for eight consecutive times, Dexa Group demonstrates long-term consistency in building public trust. This commitment has once again led Dexa Group to receive the Indonesia Public Relations Awards (IPRA) 2026 with the title of Best Public Relations 2026 in Public Trust Building through Ethical Pharmaceutical Practices. This…
28 September 2022
Dexa Group is Committed to Improving Health Services through Renovation Assistance for Inpatient Rooms at TNI AD Hospital, dr. AK Gani Palembang
Following the 53rd anniversary, Dexa Group and the Indonesian Army Health Center officially opened the renovated inpatient room at the Tk II Hospital, dr. AK Gani, Palembang. Dexa Group's devotion to providing public health services and support for the National Health Insurance (JKN) program can be seen in the refurbishment…
12 September 2022
Synergy of Dexa Group, National Population, and Family Planning Agency, and Indonesian Midwives Association to Pursue a 14% Reduction of Stunting in 2024
According to the Indonesian Toddler Nutrition Status Survey (SSGBI), the incidence of stunting in Indonesia remains at 24.4%, much behind the 14% objective set by the 2020-2024 National Medium-Term Development Plan (RPJMN). For that purpose, Dexa Group cooperated with the National Population and Family Planning Agency (BKKBN) to host a…
1 September 2022
More Than 17 Years Trusted by Indonesian Families, STIMUNO Wins Indonesian Mom’s Favorite Brand Choice Awards 2022
For more than 17 years, STIMUNO, the first phytopharmaca immunomodulator in Indonesia, had been relied on by the Indonesian Family to support the health of their immune systems. For this accomplishment, STIMUNO earned the Top 5 Indonesian Mom's Favorite Brands for Multivitamin Category in the Household & Personal Care (non-food)…
26 August 2022
Supporting Making Indonesia 4.0, Dexa Group Through Ferron Par Pharmaceuticals Accelerates The Implementation of Industry 4.0
Indonesia's Ministry of Industry accelerates seven industrial sectors, including pharmaceuticals, in implementing the Making Indonesia 4.0 roadmap to make Indonesia the top 10 big countries with the most robust economy globally by 2030. In line with this effort, as Indonesia's leading international pharmaceutical company, Dexa Group has implemented industry 4.0…
24 August 2022
Dexa Group Consistently Maintains Natural Ingredient Quality for Indonesian Phytopharmaceutical Products
Dexa Group, as a national pharmaceutical company, is committed to meeting the quality of Indonesian natural raw materials as the content of Indonesian Indigenous Modern Medicines, beginning with cultivation, harvesting, and post-harvest processes and continuing through the manufacturing process by Good Traditional Medicine Manufacturing standards (CPOTB). This is necessary to…
12 August 2022
The Ministry of Health Continues to Encourage the Use of Phytopharmaceuticals in Health Service Facilities
The government primarily focuses on developing phytopharmaceuticals to create a system of health resilience and domestic pharmaceutical self-reliance. Launching the Phytopharmaca Formulary and promoting its usage in medical institutions are examples of the government's commitment to fostering the use of phytopharmaceuticals. The Director General of Pharmaceuticals and Medical Devices at…
5 August 2022
Dexa Group’s Commitment to Encourage the Production of Natural Medicine Raw Materials for National Independence
With more than 28000 plant species and 2,848 medicinal plants, Indonesia has the second-highest biodiversity in the world. Its natural resources hold tremendous promise for developing phytopharmaceuticals and herbal medicines, including Indonesia Indigenous Modern Medicine (IIMM). Penny K. Lukito, head of the Food and Drug Supervisory Agency (BPOM), stated that…